(NASDAQ: IMVT) Immunovant's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Immunovant's revenue in 2023 is $0.On average, 4 Wall Street analysts forecast IMVT's revenue for 2026 to be $8,581,635,011, with the lowest IMVT revenue forecast at $1,994,888,015, and the highest IMVT revenue forecast at $11,789,947,295. On average, 4 Wall Street analysts forecast IMVT's revenue for 2027 to be $47,592,328,351, with the lowest IMVT revenue forecast at $12,495,897,513, and the highest IMVT revenue forecast at $83,018,588,388.
In 2028, IMVT is forecast to generate $94,833,417,535 in revenue, with the lowest revenue forecast at $32,569,186,920 and the highest revenue forecast at $165,850,562,887.